logo
Block Unveils Proto Rig and Proto Fleet, Marking a New Era in Bitcoin Mining

Block Unveils Proto Rig and Proto Fleet, Marking a New Era in Bitcoin Mining

Business Wire3 days ago
DALTON, Ga.--(BUSINESS WIRE)-- Block, Inc. (NYSE: XYZ) today unveiled Proto Rig, a first-of-its-kind modular bitcoin mining system, and Proto Fleet, a free and open-source fleet management software. The announcement, made during an event held at Proto customer Core Scientific's facility in Dalton, GA, where Proto Rigs are mining as part of their fleet, represents a significant step toward decentralizing bitcoin mining hardware, opening access to more builders, and increasing network resiliency. These mark the first two end-to-end releases by Proto, Block's suite of bitcoin mining products and services, following its initial chip sale to Core Scientific.
Proto Rig: Durable, repairable, upgradeable infrastructure
Moving away from disposable hardware models, Proto Rig is designed to be infrastructure—a paradigm shift that solves many existing pain points for miners and signals the company's long-term commitment to the industry.
Proto Rig's modular design lets operators upgrade individual hashboards without replacing entire units, transforming what has historically been a 3-5 year disposable asset into a 10-year infrastructure investment, reducing costs by 15-20% each upgrade cycle. It also allows for easy, in-place, tool-free repair, turning a process that can take hours, days, or weeks into one that takes seconds, saving miners valuable time and resources.
'Mining hardware hasn't really changed in years,' said Thomas Templeton, Hardware Lead at Block. ' Machines break often, are hard to repair, expensive and time-consuming to upgrade, and don't make the most efficient use of power or space. With Rig, we set out to change all of that–and contribute to hardware decentralization in the process.'
With unmatched power density and maximum miner uptime, Proto Rig delivers 1.5 times the power per foot of rack space compared to traditional mining hardware. Designed to be compatible with modern and legacy infrastructure, Proto Rig gives mining operators the power to maximize efficiency in their existing facilities without requiring extensive retrofitting, addressing long-standing challenges in power utilization and lifecycle management.
Proto Fleet: Comprehensive, open source, and free
Alongside Proto Rig, Block also announced Proto Fleet, comprehensive, open-source fleet management software that brings together power-scaling, monitoring, diagnostics, and maintenance tools in a single, intuitive platform.
'Mining hasn't really caught up with advances in software more broadly,' said Templeton. ' We saw an opportunity to make mining software something modern that improves operational efficiency instead of unnecessarily complicating things.'
Proto Fleet brings together many functionalities that have historically required their own, individual pieces of software to manage, helping miners streamline operations, maximize uptime, and minimize time spent troubleshooting. A big part of Proto's effort to decentralize mining, Proto Fleet will be available for anyone to use, at no cost, giving mining operators of all sizes access to powerful fleet management software. All of these advancements together—on-rack, tool-free repairability, high-quality components, swappable hashboards, and backwards compatibility—mean more uptime across install, repairs, upgrades, and ultimately the life of the machine.
The reveal of both products builds on Block's long track record of building transformational technology and rounds out the company's broader commitment to bitcoin across Square, Cash App, Bitkey, and Spiral.
For more information about Proto Rig and Proto Fleet, visit https://proto.xyz.
About Proto
Proto Global, LLC, as an affiliate of Block, Inc. is Block's suite of bitcoin mining products and services. Its mission is to decentralize mining by increasing access to tools for builders, regardless of their size or location. By entering the mining hardware space, Proto is taking a key step toward that goal. Learn more at proto.xyz.
About Block
Block, Inc. builds technology to increase access to the global economy. Each of our brands unlocks different aspects of the economy for more people. Square makes commerce and financial services accessible to sellers. Cash App is the easy way to spend, send, and store money. Afterpay is transforming the way customers manage their spending over time. TIDAL is a music platform that empowers artists to thrive as entrepreneurs. Bitkey is a simple self-custody wallet built for bitcoin. Proto is a suite of bitcoin mining products and services. Together, we're helping build a financial system that is open to everyone.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jack Dorsey Advocates for Bitcoin Use as Everyday Currency 'As It Was Designed to Be'
Jack Dorsey Advocates for Bitcoin Use as Everyday Currency 'As It Was Designed to Be'

Yahoo

time13 minutes ago

  • Yahoo

Jack Dorsey Advocates for Bitcoin Use as Everyday Currency 'As It Was Designed to Be'

Block CEO Jack Dorsey has once again emphasized his stance on Bitcoin (CRYPTO: BTC), advocating for its use as everyday money, a vision originally proposed by Bitcoin's creator, Satoshi Nakamoto. What Happened: Dorsey stressed that Bitcoin's ultimate purpose should be for daily transactions, not merely speculative trading. 'We want Bitcoin to become p2p electronic cash and everyday money, as it was designed to be,' Dorsey stated in a post on comments were in response to a post by Entropy Capital regarding how Block has developed a comprehensive Bitcoin ecosystem. This system comprises Square, a platform that allows merchants to accept Bitcoin payments, and Cash App, a wallet designed for quick and inexpensive transactions. Other elements include Bitkey, a self-custody hardware wallet for offline Bitcoin storage, and Proto, a Bitcoin mining infrastructure. Also Read: Jack Dorsey Says Bluesky's Rapid Expansion Fueled by X Exodus: 'Not a Great Way To Build a Product' Dorsey's message is unequivocal: Bitcoin is destined to become a part of everyday transactions, and Block is strategically positioning itself to facilitate this transition. Simultaneously, Treasury Secretary Scott Bessent has indicated that the U.S. is dedicated to exploring ways to accumulate more Bitcoin. At the time of writing, Bitcoin was trading at $118,473.47, a slight dip from its intraday peak of $119,399.29. Why It Matters: Dorsey's renewed emphasis on Bitcoin's intended use as everyday money underscores the growing acceptance of cryptocurrencies in the mainstream financial landscape. With Block's comprehensive Bitcoin ecosystem, the company is well-positioned to lead the charge in this transition, potentially influencing other companies to follow suit. Furthermore, the U.S. Treasury's interest in accumulating Bitcoin signals a shift in governmental attitudes towards cryptocurrencies, potentially paving the way for more widespread adoption and regulatory clarity. Read Next Here Is How Twitter CEO Jack Dorsey Plans To Expand Bitcoin Trading Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Jack Dorsey Advocates for Bitcoin Use as Everyday Currency 'As It Was Designed to Be' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.

EQT Corporation's (NYSE:EQT) high institutional ownership speaks for itself as stock continues to impress, up 3.0% over last week
EQT Corporation's (NYSE:EQT) high institutional ownership speaks for itself as stock continues to impress, up 3.0% over last week

Yahoo

time43 minutes ago

  • Yahoo

EQT Corporation's (NYSE:EQT) high institutional ownership speaks for itself as stock continues to impress, up 3.0% over last week

Explore EQT's Fair Values from the Community and select yours Key Insights Significantly high institutional ownership implies EQT's stock price is sensitive to their trading actions A total of 15 investors have a majority stake in the company with 50% ownership Insiders have sold recently AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. A look at the shareholders of EQT Corporation (NYSE:EQT) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 88% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. And last week, institutional investors ended up benefitting the most after the company hit US$33b in market cap. The one-year return on investment is currently 67% and last week's gain would have been more than welcomed. Let's take a closer look to see what the different types of shareholders can tell us about EQT. See our latest analysis for EQT What Does The Institutional Ownership Tell Us About EQT? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that EQT does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at EQT's earnings history below. Of course, the future is what really matters. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. EQT is not owned by hedge funds. The Vanguard Group, Inc. is currently the largest shareholder, with 12% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 7.6% of common stock, and Wellington Management Group LLP holds about 6.9% of the company stock. After doing some more digging, we found that the top 15 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of EQT The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our most recent data indicates that insiders own less than 1% of EQT Corporation. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Though their holding amounts to less than 1%, we can see that board members collectively own US$229m worth of shares (at current prices). In this sort of situation, it can be more interesting to see if those insiders have been buying or selling. General Public Ownership The general public-- including retail investors -- own 11% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: While it is well worth considering the different groups that own a company, there are other factors that are even more important. I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

1 Stock Down 40% This Year to Buy and Hold
1 Stock Down 40% This Year to Buy and Hold

Yahoo

timean hour ago

  • Yahoo

1 Stock Down 40% This Year to Buy and Hold

Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store